Sagefield Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Sagefield Capital’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-104,065	Closed	-$4.19M	–	111
2026 Q1	$4.19M	Buy	+104,065	New	+$2.24M	0.3%	81

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sagefield Capital's APLS Position: Q2 2026 in Review

Sagefield Capital sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 104,065 shares — an estimated $4.19M sold.

Sagefield Capital first reported a position in APLS in Q1 2026 and held it in 1 quarter. The position peaked at $4.19M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Sagefield Capital reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Sagefield Capital sold 104,065 Apellis Pharmaceuticals shares in Q2 2026, an estimated $4.19M.
Sagefield Capital first reported a position in Apellis Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Sagefield Capital's Apellis Pharmaceuticals position peaked at $4.19M in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Sagefield Capital's 13F filing for Q2 2026, filed 14 Aug 2026.